WASHINGTON — Politicians spent the better part of 2019 bickering over the best way to lower drug prices. But in the meantime, states, advocates — even the drug and insurance industries — were devising novel strategies for solving this perplexing challenge.
2020 will be the year many of those experimental ideas are tested. If they pan out, they’ll undoubtedly be models for other states or companies — and perhaps serve as inspiration for Washington, too. Below, STAT looks at three of the most interesting ideas.
Ending hepatitis C
The World Health Organization in 2016 adopted a strategy for eliminating hepatitis C, a viral liver disease and a leading cause of liver cancer, by 2030. Two states are hoping to test that theory in the coming months.